Psychological & Psychiatric Screening

Trauma-Informed Intake: How You Ask Matters as Much as What You Ask

Most people arriving at a readiness evaluation for psychedelic-adjacent care are disclosing combat exposure, sexual trauma, moral injury, or years of failed treatment — often for the first time, to a stranger. A rushed or clinically cold intake can retraumatize before you ever reach the psychiatric-risk questions you actually need answered. Framing an intake around safety, choice, and collaboration is associated with better provider recognition of PTSD and depression and higher rates of guideline-concordant, trauma-informed care delivery in primary-care trials Plausible — though that same trial found trauma-informed process improved diagnosis and care delivery without a measurable difference in 12-week symptom outcomes, so treat it as good practice, not a proven treatment effect in itself.

• Screen in a private, unhurried setting; explain why each question is being asked before you ask it.
• Offer choice: "You can decline to go into detail — I only need to know if this happened, not the story" lets the patient keep control of disclosure.
• Use the patient's own language for their experience rather than imposing a diagnostic label early.
• Watch for dissociation or activation during the interview (blank affect, dissociative pauses, escalating distress) and have a grounding technique ready before continuing.
• Explain what happens after a positive safety-screen answer before you ask the question, so disclosure doesn't feel like a trap.

The C-SSRS: Your Non-Negotiable Suicide Screen

The Columbia-Suicide Severity Rating Scale (C-SSRS) is the field's gold-standard suicide-risk instrument, validated across adolescent and adult, psychiatric and general-medical populations Established, and it is the mandated suicide screen across the entire Veterans Health Administration. It separates two constructs that matter clinically: ideation severity (from a passive wish to be dead through active ideation with a specific plan and intent) and behavior — preparatory acts, aborted or interrupted attempts, and actual attempts, both lifetime and recent.

Administer the full C-SSRS at intake, and repeat a brief "since we last talked" screener at every subsequent contact — dosing day, daily or weekly check-ins, and every follow-up visit. This is not a one-time gate; risk changes over the course of preparation and treatment.

• Ask every item in sequence — do not skip ahead based on assumption, even if the patient presents as stable.
• A "yes" to active ideation with plan and/or intent, or any preparatory behavior or attempt (recent or lifetime), is an immediate stop point pending psychiatric evaluation — not a note for later.
• Document the exact item endorsed, not just a risk category label, so the next clinician who reads the chart knows precisely what was disclosed.
• Have a written safety plan and crisis-line information ready before you start screening, not after a positive result. Veterans Crisis Line: 988, then press 1.

Personal & Family History of Psychosis or Bipolar Disorder

Across every hallucinogen-type substance covered in this standard, personal or family history of a psychotic disorder or bipolar disorder is the single most consistent psychiatric red flag for destabilization Established. Absolute risk in a monitored clinical setting is low — pooled data across contemporary psychedelic trials put psychedelic-induced psychosis at roughly 0.002% in population-based studies and 0.2%–0.6% across uncontrolled and randomized trials — but that risk concentrates sharply in people who already carry psychotic-spectrum vulnerability: in trials that enrolled participants with schizophrenia, roughly 4 in 100 went on to develop long-lasting psychotic symptoms. Serious adverse events overall — including new-onset psychosis, mania, and suicidal behavior — cluster almost entirely in participants with a pre-existing neuropsychiatric diagnosis (around 4%), versus essentially none reported in healthy volunteers.

Whether a history of schizophrenia should remain an absolute research-exclusion criterion is an open, actively studied question, and some recent meta-analytic reviews argue for a more individualized approach going forward Hypothesis — but that is a research-design debate, not a clinical green light. Until better-quality data exist, active psychosis or unmanaged bipolar disorder remains a stop point in this standard Established.

• Ask directly, every time: personal history of psychotic episodes, schizophrenia, or schizoaffective disorder.
• Ask directly: personal history of manic or hypomanic episodes, diagnosed or undiagnosed.
• Ask about first-degree relatives (parent, sibling, child) with schizophrenia or bipolar I disorder — family loading raises concern even with a clean personal history.
• Ask about prior psychiatric hospitalization for psychosis or mania, and about current psychotic symptoms (delusions, hallucinations) regardless of whether they've ever been formally diagnosed.
• A positive family history alone is a flag for closer evaluation and physician discussion, not an automatic permanent disqualification — but active personal psychosis or unmanaged bipolar disorder is a stop point pending psychiatric clearance.

The Contraindication & Stop Framework

This standard flags domains; it does not set the numbers. The universal stop-framework domains are: significant or uncontrolled cardiovascular disease or arrhythmia, uncorrected electrolyte abnormalities, significant hepatic or renal impairment, active psychosis or unmanaged bipolar disorder, acute suicidality, pregnancy, and contraindicated concurrent medications that cannot be safely managed. The treating physician sets the exact threshold for each domain and makes the final go/no-go call — this module documents readiness, it does not clear anyone for treatment.

Medication reconciliation is where psychiatric screening and pharmacology intersect most dangerously. MDMA acts as a releasing agent at the serotonin, dopamine, and norepinephrine transporters, driving a large surge in synaptic serotonin Established. Layer an SSRI, SNRI, or MAOI on top of that and you raise the risk of serotonin syndrome — a triad of neuromuscular excitation (tremor, hyperreflexia, clonus), autonomic instability (tachycardia, hyperthermia, blood-pressure swings), and altered mental status (agitation, delirium) that can be fatal if unrecognized Established. A supervised, prescriber-directed taper — never a patient-directed one — is the standard of care before MDMA or ibogaine in a patient on serotonergic medication.

• Complete full medication and supplement reconciliation at intake, and repeat it before the treatment day, not just once at screening.
• Flag SSRIs, SNRIs, and MAOIs specifically. Note that SSRI pretreatment can also blunt MDMA's subjective effects, since both act on the same serotonin transporter — worth setting realistic expectations if a taper isn't fully complete.
• Remember that abruptly stopping an SSRI carries its own risk — discontinuation symptoms and relapse of the underlying condition — so the taper decision and its timing belong to the prescriber, weighing both risks.
• Cross-check every stop-framework domain explicitly in the chart. "Reviewed, no contraindication found" is not the same as leaving it blank.

Genuinely Informed Consent: Benefits, Honest Risks, and What's Still Unknown

A signature is not consent. Genuine informed consent for this population requires three components delivered honestly and specifically, not as boilerplate: what benefit is realistically expected and how strong that evidence actually is; what the specific modality's signature risks are (cardiac for ibogaine, serotonergic and thermal for MDMA, bladder and dependence for ketamine, psychological destabilization risk for psilocybin and LSD, and so on); and what remains unknown, named as unknown rather than glossed over.

Be precise and current about legal and regulatory status when you disclose it — patients deserve accuracy, not the exaggerated legitimacy that hype cycles create. Psilocybin, MDMA, LSD, DMT, and ibogaine remain Schedule I under federal law; MDMA-assisted therapy has completed only Phase 3 trials and is not FDA-approved; ketamine is Schedule III and used off-label for psychiatric indications; esketamine (Spravato) is the one FDA-approved option in this space, approved specifically for treatment-resistant depression, not for the other indications sometimes discussed alongside it. Never let a patient walk away believing "in trials" means "proven" or "approved."

• State the benefit claim's evidence grade out loud — established, plausible, or hypothesis — don't let optimism round it up.
• Walk through the modality-specific risk annex line by line; don't compress serious risks into a single soft sentence.
• Name the honest unknowns explicitly: whether preparation itself changes treatment outcomes, and whether neuroplasticity benefits seen in animal models translate into durable human benefit, are both open hypotheses this field's registries are built to test — not settled facts.
• Confirm the patient (and caregiver, where involved) can accurately restate the key risks back to you — teach-back, not just a signature.
• Document that consent was voluntary and that withdrawal is possible at any point without penalty to future care.

Documentation, Escalation, and the Clinician's Final Call

Assemble a clear-to-treat packet before any modality-specific step proceeds: screening results, medication reconciliation, contraindication review, the relevant modality annex, and completed education and consent. A named, licensed clinician-of-record reviews and signs it. This standard documents readiness — it does not clear anyone, and it never substitutes for your own clinic's screening and consent process.

Any safety flag — a positive C-SSRS item, a destabilization sign, a newly identified contraindication — triggers immediate escalation to the care team. It is never a data point held for the next scheduled visit.

• All Phase 1 screens (medical, cardiovascular, psychiatric, medication/substance, consent/education) completed and reviewed before any preparation step begins.
• Every contraindication domain addressed with an explicit clinician decision in the chart, not left blank.
• An escalation plan and crisis-line information given to the patient and caregiver in writing, before it's needed.
• C-SSRS re-screening scheduled at every subsequent contact, not just at intake.